Associate Professor, Medicine, University of Arizona College of Medicine
Hematology
Dr. Daruka Mahadevan, MD
|
|
Give Review
Dr. Daruka Mahadevan works in the field of Hematology. Daruka Mahadevan is also published. He has 53 publications published. The lastest publication: "Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and-resistant prostate cancer.' Daruka Mahadevan accepts Medicare payments and is listed with Medicare.gov.
Publications
- Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and-resistant prostate Cancer.
- P8.07Novel mutational profiles in relapsed/refractory advanced Cancer patients' pre- and post-targeted therapy.
- Ezatiostat hydrochloride for the treatment of Myelodysplastic syndromes.
- Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
- Novel Mutations in a Patient with ALK-Rearranged Lung Cancer.
- First-in-Human Phase 1 Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors.
- Genetic and cytokine changes associated with symptomatic stages of CLL.
- Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with ...
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas.
- Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for palliative treatment of malignant ascites from gastrointestinal stromal tumours.
- An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.
- Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cel...
- Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-Cell malignancies.
- Novel targeted therapies and combinations for the treatment of multiple myeloma.
- Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin Lymphoma: Southwest Oncology Group Study S0...
- Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma.
- Phase I Trial of AEG35156 an Antisense Oligonucleotide to XIAP Plus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
- Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Potentially Curative in Mice with Aggressive DLBCL Co-Overexpressing MYC and BCL2.
- Targeting aurora2 kinase in oncogenesis: a structural bioinformatics approach to target validation and rational drug design.
- Structure-based design of novel anti-Cancer agents targeting aurora kinases.
- Specific inhibition of the Akt1 pleckstrin homology domain by D-3-deoxy-phosphatidyl-myo-inositol Analogues.
- Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies.
- Thioredoxin-1 binds to the C2 domain of PTEN inhibiting PTEN's lipid phosphatase activity and membrane binding: a mechanism for the functional loss of PTEN's tumor sup...
- In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316.
- Efficacy of lenalidomide in Myelodysplastic syndromes.
- A conserved glutamate residue in transmembrane helix 10 influences substrate specificity of rabbit OCT2 (SLC22A2).
- Strategies for targeting the multidrug resistance-1 (MDR1)/P-gp transporter in human malignancies.
- Amino acid changes in Drosophila alphaPS2betaPS integrins that affect ligand affinity.
- Transcript profiling in peripheral T-cell Lymphoma, not otherwise specified, and diffuse large B-cell Lymphoma identifies distinct tumor profile signatures.
- Actin microfilament aggregation induced by withaferin A is mediated by annexin II.
- Will MDR-1/P-gp modulators provide clinical benefit in hematologic malignancies?
- Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to Acute myelogenous leukemia.
- Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach.
- Modulation of ligand binding by alternative splicing of the alphaPS2 integrin subunit.
- Tumor-stroma interactions in pancreatic Ductal adenocarcinoma.
- Monoclonal antibody therapies targeting pancreatic Ductal adenocarcinoma.
- Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis.
- Variation in cytotoxic T-lymphocyte responses to peptides derived from tyrosinase-related protein-2.
- Discovery of a novel class of AKT pleckstrin homology domain inhibitors.
- Design and activity of a murine and humanized anti-CEACAM6 single-chain variable fragment in the treatment of pancreatic Cancer.
- MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate Cancer.
- An orally active small molecule TGF-beta receptor I antagonist inhibits the growth of metastatic murine breast Cancer.
- Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
- Translational advances and novel therapies for pancreatic Ductal adenocarcinoma: hope or hype?
- The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma Cells.
- AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in Leukemia cell lines and patient samples.
- Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration.
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell Lymphoma.
- Novel therapeutics for aggressive non-Hodgkin's Lymphoma.
- CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor Cells.
- Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic Leukemia.
- An analog of withaferin A activates the MAPK and glutathione "stress" pathways and inhibits pancreatic Cancer cell proliferation.
Schools
University Of London Kings College School Of Medical amp Dental
University Conn
University Of Connecticut Health Sciences Center
University Of Arizona Cancer Center
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
- Hematology
Accepted Insurances
Education
-
University of Arizona -
University of Connecticut
Hospital
-
University of Tennessee Medical Center
Drug Facts
| NPI NUMBER | 1841398302 | |
| NPPES Provider LastName | MAHADEVAN | |
| NPPES Provider FirstName | DARUKA | |
| NPPES Provider ZIPCode | 857240001 | |
| NPPES Provider State | AZ | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 166.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1841398302 |
| Last Name Of The Provider | MAHADEVAN |
| First Name Of The Provider | DARUKA |
| View All |
Similar Doctors
|
Dr. Parminder Singh, MD |
|
|
Dr. Jonathan E. Schwartz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Boxer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lee D. Cranmer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria C. Bishop, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel O. Persky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew M. Yeager, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ursa A. Brown-Glaberman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alison T. Stopeck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dennis L. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine A. Azar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Alberts, MD |
|
|
Dr. Linda Garland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas D. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Veronique Poulin, MD
This Doctor is OpenDoctor Recommended.
|